Imunon (Nasdaq: IMNN) is a clinical-stage biotech developing DNA-based immunotherapies and non-viral gene delivery. It's raising capital through this offering to fund operations and pipeline work.

Lead candidate IMNN-001 showed a 14.7-month median overall survival benefit in final Phase 2 OVATION 2 data (45.1 vs 30.4 months), with a 24.2-month benefit in patients also on PARP inhibitors. A pivotal Phase 3 is underway. Risk: future stock sales could cause significant dilution, and buyers in this offering face immediate and substantial dilution in book value per share. There's also going-concern risk and a need for additional capital. Use of proceeds: funding operations, R&D, and clinical trials. Bottom line: late-stage data and a registrational program in a selective but reopened biotech IPO window. Dilution and cash runway are the things to watch.

Lead candidate IMNN-001 showed a 14.7-month median overall survival benefit in final Phase 2 OVATION 2 data (45.1 vs 30.4 months), with a 24.2-month benefit in patients also on PARP inhibitors. A pivo